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Abstract
Introduction The use of thiopurines is frequently ac-
companied by hepatotoxicity. Studies on hepatocyte
cultures showed a time- and dose-dependent increase
of thiopurine toxicity. 5-Aminosalicylic acid (5-ASA)
and allopurinol can influence thiopurine metabolism;
however, it is unknown whether this affects in vitro
cytotoxicity.
Methods Human hepatoma cells (Huh7, HepG2 and
HepaRG) were incubated with increasing concentra-
tions of thiopurines, 5-ASA or allopurinol. Water-
soluble tetrazolium salt-1 (WST-1) cytotoxicity assays
were used to calculate cell survival curves and half
maximal inhibitory concentrations (IC50). Combination
experiments with thiopurines with a fixed dose of
200 μM 5-ASA or 100 μM allopurinol were conducted
in HepaRG cells. Caspase-3/7 activation was evaluated,
and single cell electrophoresis analysis was performed.
Results A time- and dose-related cytotoxic effect was
seen with azathioprine (AZA) in all hepatoma cells,
whereas Huh7 and HepG2 cells did not show toxicity
to 6-mercaptopurine (6-MP). HepaRG cells expressed
the highest levels of drug metabolising enzymes, and
therefore, combination experiments were conducted in
HepaRG cells. Addition of a non-toxic dose of allopu-
rinol resulted in a twofold to threefold increased cyto-
toxicity of all thiopurines, which seemed to be mediated
by apoptosis/DNA damage.
Conclusion The addition of allopurinol to thiopurines
leads to a two–threefold increased cytotoxicity in
HepaRG cells.
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Abbreviations
5-ASA 5-Aminosalicylic acid
6-MP 6-Mercaptopurine
6-TGN 6-Thioguanine nucleotide
AZA Azathioprine
TG Thioguanine
6-MMP 6-Methylmercaptopurine
TMPT Thiopurine-S-methyltransferase
XO Xanthine oxidase
DMSO Dimethyl sulfoxide
Introduction
The metabolism of azathioprine (AZA) and 6-
mercaptopurine (6-MP) is complex and involves multi-
ple enzymatic steps, before the pharmacologically
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active substrate 6-thioguanine nucleotide (6-TGN) is
produced (see Fig. 1). During this process, side products
such as 6-methylmercaptopurine ribonucleotides (6-
MMP) and thiouric acid are also formed. The metabo-
lism of thioguanine (TG) is less complex with the main
pathway resulting in a more direct conversion to 6-
TGN. Several factors may influence thiopurine metab-
olism such as genetic variants in the thiopurine-S-
methyltransferase (TPMT) gene and the use of concom-
itant drugs (Sahasranaman et al. 2008).
With respect to inflammatory bowel disease (IBD),
the most relevant drugs that can influence thiopurine
metabolism are 5-aminosalicylic acid (5-ASA) and allo-
purinol. Allopurinol, a strong xanthine oxidase (XO) and
TPMTinhibitor, reduces 6-MMP formation (Blaker et al.
2013). The combination of allopurinol with a tailored
dosage of AZA or 6-MP is a potent strategy in patients
with a skewed metabolism towards the cytotoxic 6-
MMP formation. Hoentjen et al. showed a significant
reduction of 6-MMP levels from 10,110 pmol/8×108 red
blood cell (RBC) with monotherapy to 265 pmol/8×108
RBC with combination therapy and significant increase
of 6-TGN levels from 145 to 271 pmo1/8×108 RBC
(Hoentjen et al. 2013). Thiopurines and 5-ASA exert
their disease-modifying effect by different mechanisms,
yet 5-ASA can interfere in thiopurine metabolism by a
non-competitive inhibition of TPMT (Szumlanski and
Weinshilboum 1995). Therefore, co-administration can
lead to a decreased production of 6-MMP and increase of
the therapeutic active 6-TGN (Lowry et al. 2001; Dewit
et al. 2002; de Graaf et al. 2010).
Studies to explore hepatotoxicity in humans on a
cellular level are costly and have major ethical consider-
ations. In vitro studies with primary cultures of
hepatocytes or hepatoma cell lines are an ethical and
feasible alternative for exploring drug toxicity. Previous
in vitro studies demonstrated a time- and dose-dependent
toxicity of AZA, 6-MP and 6-TG in HepaRG and HepG2
cells (Petit et al. 2008; de Vries et al. 2012). In this study,
we aim to explore the effects of the addition of 5-ASA or
allopurinol on thiopurine-induced hepatotoxicity.
Materials and methods
HepG2 and Huh7 cells have been used extensively in
in vitro experiments so far; therefore, we tested cytotox-
icity in these hepatoma cell lines as well as in the more
recently developed HepaRG cell line (Andersson et al.
2012). First, we assessed individual cytotoxicity of
AZA, 6-MP and TG in all three cell lines. Next, we
tested these cell lines for the expression of important
drug metabolising enzymes and used the hepatoma cell
line with the highest expression of drug metabolising
enzymes to explore the influence of 5-ASA and allopu-
rinol on cytotoxicity of thiopurines.
Cell culture
Hepatocyte-differentiated HepaRG cells (Invitrogen™,
Paisly, UK), HepG2 (HB-8065™, American Type
Culture Collection, Rockville, USA) and Huh7 cells
(JCRB0403, Cell Resource Center for Biomedical
Research, Tohoku University, Japan) were used and
cultured as described previously (Parent et al. 2004; de
Vries et al. 2012). Cells were seeded into 96-well flat
bottom microplates at a density of 1.48×105 cells/cm2
for the HepG2 and Huh7 cells and 4.5×105 cells/cm2 for
Fig. 1 Simplified overview of thiopurine metabolism.
Azathioprine (AZA) is converted by glutathione S-transferase
(GST) in 6-mercaptopurine (6-MP). 6-MP can be methylated by
thiopurine S-methyl transferase (TPMT) into 6-methyl mercaptopu-
rine (6-MMP), oxidised by xanthine oxidase (XO) into 6-thiouric
acid (6-TU) or metabolised by hypoxanthine-guanine
phosphoribosyltransferase (HPRT) into 6-thioinosine
monophosphate (6-TIMP). Next, 6-TIMP can be phosphorylated
into 6-thioinosine triphosphate (6-TITP) or metabolised into the
pharmacological active 6-thioguanine nucleotides (6-TGN).
Besides metabolised into 6-TGN by HPRT, 6-thioguanine (TG)
can be oxidised by XO into 6-TU or methylated by TMPT into 6-
methyl thioguanine (6-MTG)
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the HepaRG cells according to the manufacturer’s pro-
tocol. After 24-h incubation, the medium was replaced
by differentiation medium, being growth medium sup-
plemented with 2.0 % (v/v) dimethyl sulfoxide (DMSO)
(Sigma-Aldrich B.V.). Addition of DMSO is according
to the protocol of growing HepaRG cells. To increase
uniformity of the experiments, we also used differenti-
ation medium in HepG2 and Huh7 cell cultures.
Incubations with drugs
On the fourth day after seeding, cells were incubated
with one of the following test substances; AZA, 6-MP,
5-ASA, allopurinol (all from Sigma-Aldrich B.V.) or
TG (Alfa Aesar GmbH & Co KG, Karlsruhe,
Germany) in concentrations ranging from 0.5 μM to
4 mM. For the combination experiments, a fixed non-
toxic dose of 200 μM 5-ASA or 100 μM allopurinol
was used in combination with the same range of
thiopurines for 24, 48 or 72 h. In order to mimic daily
drug administration, medium with drugs was refreshed
every 24 h.
Evaluation of cytotoxicity
Water-soluble tetrazolium salt-1 (WST-1) assays (Roche
Diagnostics Nederland BV, Almere, the Netherlands)
were performed after 24, 48 or 72 h of incubation with
the drugs. The WST assay is based on the ability of
viable cells to cleave the tetrazolium salt WST, which
was measured with a Tecan Infinite m200PRO plate
reader (Tecan, Giessen, the Netherlands) as described
previously (de Vries et al. 2012). Three independent
experiments were conducted in triplicate.
Evaluation of drug metabolising enzymes
Protein expression of important drug metabolising en-
zymes was measured for two purposes: first to select the
cell line with the highest expression (and therefore best
comparability with human hepatocytes) and second to
quantify any influence of adding DMSO to the culture
medium of HepG2 and Huh7 cells. The following en-
zymes were analysed: UDP-glucuronosyltransferase 1A
(UGT1A), cytochrome-P450 3A4 (CYP3A4), glutathi-
one S-transferase alpha (GSTAlpha), mu (GSTMu) and
theta (GSTTheta) (Eklund et al. 2006). These enzymes
were chosen because of their role in thiopurine metab-
olism (GSTAlpha and GSTMu) or their important role
in drug metabolism in general. Cells were seeded in
25 cm2 flasks, and after 24 h of culturing, half of the
flasks were supplemented with differentiation medium
(group DMSO+), while the other half received standard
William’s E growth medium (group DMSO−). On days
0, 3 and 7, cells were harvested and homogenised using
lysis buffer, consisting of 0.25 M saccharose, 20 mM
Tris–HCl pH 7.4, 1 mM dithiothreitol (DTT) and 1 %
Triton X-100 and lysates frozen at −20 °C until use.
Total amount of protein was assessed according to the
Lowry procedure (Lowry et al. 1951). Homogenates
(25 μg protein) were loaded on 8, 10 or 12 % SDS
polyacrylamide gels for UGT, CYP3A4 or GST analy-
ses, respectively. After electrophoresis, proteins were
transferred to nitrocellulose (Whatman GMBH,
Dassel, Germany) using a semi-dry blotter (V20-SDB,
Scie-Plas, Cambridge, UK). Non-specific binding was
blocked with 1 % gelatine in phosphate-buffered saline
(PBS)/Tween 20 (0.05 %, v/v). The following primary
monoclonal antibodies were added: CYP3A4 (kind gift
fromDr. P. Kremer, Université de Liège, Belgium), GST
class Theta T1-1 (purchased from Dr. E. Juronen, Tartu,
Estonia), UGT1A, GSTAlpha (A1-2) and GSTMu (all
developed in our laboratory) (Peters et al. 1987; Peters
et al. 1990; Peters et al. 1992). β-Actin (1:10,000,
Sigma-Aldrich B.V.) was used as protein loading con-
trol. After incubation and washing, polyclonal rabbit
anti-mouse peroxidase-conjugated second antibodies
(Dako Diagnostics, Glostrup, Denmark) were added.
Immunoreactive proteins were visualised with 0.1 %
(w/v) 3,3-diaminobenzidine, 5 mM imidazole, 2 mM
cobalt chloride hexahydrate and 8 μL 30 % hydrogen
peroxide in 50 mL PBS.
TPMT enzyme activity and polymorphism
To exclude influence caused by variation in TPMT
activity, we analysed TPMT polymorphisms as well as
TPMT enzyme activity. TPMT enzyme activity was
assessed by high-performance liquid chromatography
(HPLC) as described previously (Ford and Berg 2003).
Genotyping of the three common variants in the TPMT
gene (TPMT*2, *3A and *3B) was performed accord-
ing to the manufacturer’s protocol using Taqman SNP
genotyping assays (Life Technologies, Bleiswijk, the
Netherlands, (TPMT*2 : rs1800462, assay ID
C__12091552_30; TPMT*3B: rs1800460, assay ID
C__30634116_20; TPMT*3A: rs1142345, assay ID
C__19567_20). Signals were detected with 7500 Fast
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Real-Time PCR system (Life Technologies) and subse-
quently analysed using the Allelic Discrimination soft-
ware version 1.4 (Life Technologies).
Thiopurine metabolite assessment
6-MMP and 6-TGN were assessed in cell lysates
by a HPLC method as described by Dervieux et al.
(Dervieux and Boulieu 1998). Metabolite analysis
was only done for AZA, since the pharmacological
action is based on the release of 6-MP. We as-
sumed that if AZA is intracellular metabolised, 6-
MP will be too. For this purpose, HepaRG cells
were incubated with 600 μM AZA for 10 h; sub-
sequently, the cells were washed with PBS 0.9 %,
harvested, homogenised and stored at −20 °C until
use.
Caspase-3/7 activation
Caspase-3/7 activationwas tested in HepaRG cells treat-
ed with AZA with and without 5-ASA or allopurinol
(Promega) according to the manufacturer’s protocol.
Briefly, HepaRG cells were seeded in a flat-bottom 96-
well plate in a density of 20,000 cells/well. Cells were
incubated with only medium (control), AZA (70 μM),
5-ASA (200 μM), allopurinol (100 μM), a combination
of AZA+5-ASA, a combination of AZA+allopurinol or
staurosporine (2 μM) (positive control). After 24 h,
Apo-one reagent was added. Caspase-3/7 activation
was measured after 6 h on a Tecan Infinite m200PRO
plate reader (Tecan, Giessen, the Netherlands). Two
experiments were performed in triplicate. The control
was set as reference to calculate differences in caspase-
3/7 activation.
Fig. 2 Cell survival after incubation of Huh7, HepG2 and
HepaRG cells with azathioprine (AZA), 6-mercaptopurine (6-
MP) or thioguanine (TG) for 72 h. In the HepaRG cells, 5-
aminosalicylic acid (5-ASA) and allopurinol were also tested.
Values are means with SEM from three independent experiments,
performed in triplicate. SEM standard error of the mean
Table 1 IC50 values in HepG2,
HepaRG and Huh7 cells after 24,
48 or 72 h exposure to
thiopurines, 5-ASA or allopurinol
Values are expressed in μM with
95 % confidence interval.
Significantly different (P<0.05)*
or (P<0.01)** compared to 24-h
shorter incubation
AZA azathioprine, 6-MP 6-mer-
captopurine, TG thioguanine, 5-
ASA 5-aminosalicylic acid, IC50
half maximal inhibitory concen-
trations, n.r. IC50 not reached,
95 % CI 95 % confidence interval
24 h 48 h 72 h
IC50 (95 % CI) IC50 (95 % CI) IC50 (95 % CI)
HepG2 AZA 572 (520–628) 406 (333–495)** 363 (315–419)
6-MP n.r. n.r. n.r.
TG n.r. 1746 (1258–2422)** 1134 (812–1585)
Huh7 AZA 464 (431–501) 400 (314–509) 307 (188–501)
6-MP n.r. n.r. n.r.
TG 2069 (856–5004) 172 (105–280)** 242 (120–486)
HepaRG AZA 514 (460–574) 317 (289–347)** 266 (237–298)*
6-MP n.r. 679 (502–920) 412 (321–530)
TG 1949 (993–3827) 100** (80–125) 19** (16–22)
5-ASA n.r. n.r. n.r.
Allopurinol n.r. 999 (766 – 1302)** 509 (411 – 631)**
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with the Apo-ONE® Homogeneous Caspase-3/7 Assay
Comet assay
The comet assay was used to identify the mechanisms
behind the increased toxicity with allopurinol co-admin-
istration. This assay was performed according to the
manufacturer’s instructions (Trevigen Inc., Gaithersburg,
MD). HepaRG cells were seeded in 25-cm2 flasks and
treated 24 h with allopurinol (100 μM), AZA (70 μM),
AZA (70 μM)+allopurinol (100 μM) or untreated (con-
trol). After 24 h, cells were harvested and the cell suspen-
sion was mixed with 75 μL low melting agarose
(Trevigen Inc.) in a density of 2×104 cells/mL and direct-
ly pipetted on agarose-precoated slides. Slides were stored
at 4 °C for 30 min and subsequently submerged in lysis
solution. After 60-min lysis, they were treated with alka-
line unwending solution (pH>13) for 60 min, followed
by 30-min electrophoresis at 25 V. Slides were stained
with SYBR green (Trevigen Inc.) and visualised and
photographed by a digital camera (AxioCam MRm)
attached to a fluorescent microscope (Axio imager.M1)
using a 20× magnification.
Statistics
For the cytotoxicity analyses, the mean absorption of the
empty wells was used to correct for background stain-
ing. The mean of three experiments was used for further
calculations. Cell survival (in percentage of control)
was calculated by dividing the mean of each con-
centration by the mean of the control wells (cells
without drugs). Half maximal inhibitory concentra-
tions (IC50) were calculated and subsequently tested
among experiments using the extra sum of squares
F test. Differences in caspase-3/7 activation were
compared means of the by Mann–Whitney U test.
Analyses were performed with GraphPad Prism
(version 5.03 for Windows, GraphPad Software,
San Diego, California, USA; www.graphpad.com).
Fig. 3 Expression of β-actin, GSTAlpha, GSTMu, GSTTheta,
CYP3A4 and UGT1A in HepG2, Huh7 and HepaRG cells at day
0, after 3 days of incubation with William’s E medium without
DMSO (3−) orWilliam’s with DMSO 2% (3+) and after 7 days of
incubation without (7−) and with (7+) DMSO.M rainbow marker
(Precision Plus Protein™ Kaleidoscope™) or antigen for the
specific antibody (GST Alpha, Mu and Theta). GSTAlpha gluta-
thione S-transferase alpha, GSTMu glutathione S-transferase Mu,
GSTTheta glutathione S-transferase Theta, CYP3A4 cytochrome-
P450 3A4, UGT1A UDP-glucuronosyltransferase 1A, DMSO di-
methyl sulfoxide
Fig. 4 Cell survival curves after incubation of HepaRG cells with
AZA, 6-MP or TG for 72 h with and without a fixed non-toxic
concentration of 200 μM 5-ASA or 100 μM allopurinol. Values
are means with SEM from three independent experiments,
performed in triplicate. AZA azathioprine, 6-MP 6-mercaptopu-
rine, TG thioguanine, 5-ASA 5-aminosalicylic acid, SEM standard
error of the mean
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Results
Single-drug tests
AZA showed a steep decline in cell survival at concen-
trations above approximately 200 μM in all cell lines
(Fig. 2), with a time-dependent effect (Table 1). With
respect to 6-MP, cell survival was not affected in the
HepG2 and Huh7 cells; however, in the HepaRG cells, a
decline in cell survival was seen when incubating for 48
or 72 h (Table 1). Incubation with TG resulted in a dose-
dependent decline of cell survival observed in all cell
lines, with the most pronounced decline in HepaRG
cells. The lowest IC50 value (i.e. most cytotoxicity)
was found in the HepaRG cells incubated for 72 h with
TG, with an IC50 of 19 μM (Table 1).
Expression of drug metabolising enzymes
Large differences were seen between the three cell lines
regarding the expression of UGT1A, CYP3A4,
GSTAlpha, GSTMu and GSTTheta (Fig. 3). Huh7 and
HepaRG cells showed CYP3A4 expression, whereas
HepG2 cells did not. The HepaRG cells showed the
highest expression of GSTAlpha and GSTMu.
GSTTheta was expressed in both HepaRG and HepG2
cells but not at all in Huh7 cells. The latter was con-
firmed by PCR analysis, which showed a GSTT1 gene
deletion in Huh7 cells (data not shown). In HepG2 and
Huh7 cells, addition of DMSO to the culture medium
increased the expression of GST and UGTA1 enzymes.
Overall, HepaRG cells showed the highest expression of
all enzymes.
Combination tests of thiopurines with 5-ASA
or allopurinol
Based on the highest expression of drug metabolising
enzymes, HepaRG cells were used for the combination
experiments with 5-ASA and allopurinol. 5-ASA did
not influence cell survival of HepaRG cells at all, while
incubation with allopurinol gave a decline in cell sur-
vival after 48 and 72 h with concentrations above
300 μM (Fig. 2 and Table 1). As can be seen in Fig. 4
and Table 2, incubation of thiopurines in combination
with a fixed, non-toxic dose of 100 μM allopurinol had
a larger influence on cytotoxicity than concomitant in-
cubation with 200 μM 5-ASA. Co-administration of
allopurinol with all thiopurines consistently resulted in Ta
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an increased cytotoxicity, with the most pronounced
cytotoxic effects emerging after 48 or 72 h. The combi-
nation of 6-MP and 5-ASA but not AZA and 5-ASA
showed an increase in IC50 (i.e. decreased cytotoxicity)
after 48 or 72 h incubation.
TPMT activity and genotype
No mutations were found for the three most com-
mon allele variants in TPMT. TPMT activity was
expressed as nmol 6-methylthioguanine/mg protein
per hour and was lowest in HepG2 cells (0.08 nmol/
mg protein per hour), followed by HepaRG cells
(0.28 nmol/mg protein per hour) and Huh7 cells
(0.47 nmol/mg protein per hour). Values were com-
parable with these found in other cell lines (Karim
et al. 2013). TPMT activity was not correlated with
the cytotoxicity.
Metabolite formation
Support for in vitro metabolism of the thiopurines was
obtained by HPLC. The retention time of 6-TGN was
comparable to AZA and 6-MP; therefore, only 6-MMP
metabolites could be identified by HPLC. In the culture
medium of HepaRG cells incubated with AZA, we
demonstrated the presence of 6-MMP metabolites, pro-
viding evidence for in vitro metabolism of AZA in
HepaRG cells (Fig. 5).
Mechanisms behind the increased cytotoxicity
of allopurinol co-administration
DNA damage by AZA with or without allopurinol
was visualised with single cell electrophoreses
(Fig. 6). With levels of AZA (70 μM) not affecting
cell viability, the combination of AZA+allopurinol
resulted in larger comet tails (more DNA damage)
than incubation with AZA alone. In addition, cas-
pase-3/7 activation was significantly increased
(P<0.01) when allopurinol (100 μM) was co-
administered with AZA (70 μM), while allopurinol
alone did not increase caspase-3/7 activation
(Fig. 7). Co-administration of 5-ASA (200 μM)
with AZA (70 μM) did not influence caspase-3/7
activation (P=0.17).
Fig. 5 Formation of 6-MMP (RT: 5.935) metabolites, measured
byHPLC in culture medium ofHepaRG cells after incubation with
AZA for 10 h. The RT of AZA and 6-MP is equal to that of 6-
TGN; therefore, only 6-MMP metabolites could be distinguished.
Other peaks are substances of culture medium. 6-MMP 6-
methylmercaptopurine, RT retention time, AZA azathioprine, 6-
MP 6-mercaptopurine, 6-TGN thioguanine nucleotide
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Discussion
In this study, we showed that the combination of a non-
toxic dose of 100 μM allopurinol with AZA, 6-MP or
TG led to a twofold to threefold increase in thiopurine-
induced cytotoxicity in HepaRG cells. The most likely
explanation for the increased cytotoxicity with allopuri-
nol is an elevation of 6-TGN levels, which are incorpo-
rated into DNA as fraudulent bases, resulting in strand
breakage and apoptosis (Sahasranaman et al. 2008).
Previous studies in cultures of rat hepatocytes
showed a positive effect on cell viability when allopuri-
nol was co-administered with AZA, due to its anti-
oxidant capacities (Lee and Farrell 2001; Tapner et al.
2004; Al Maruf et al. 2014). The contrasting findings of
our study might be explained by differences in the
experimental settings. Isolated rat hepatocytes exert no
mitotic activity in contrast to human hepatoma cells.
Because 6-TGNs act through incorporation into the
DNA, this effect may bemore pronounced inmitotically
active cells. We hypothesise that the higher levels of 6-
TGNs with allopurinol co-administration are responsi-
ble for the increased cytotoxicity. This is supported by
our findings that allopurinol co-administration re-
sulted in more single-strand breakages and signif-
icant increased caspase-3/7 activation. In vivo, co-
administration of allopurinol results in a significant
reduction of 6-MMP metabolites and increase of 6-
TGN metabolites (Hoentjen et al. 2013). Unfortunately,
we were not able to analyse 6-TGN levels by HPLC,
because of equal retention times of AZA, 6-MP and 6-
TGN. A direct comparison of our in vitro study with
in vivo situation is difficult because of low mitotic activ-
ity of human hepatocytes compared with our human
hepatoma cells. However, HepaRG cells are known to
have decreased mitotic activity when they are confluent,
resembling the in vivo situation as best as possible.
(Andersson et al. 2012).
Theoretically, addition of 5-ASA may lead to de-
creased hepatotoxicity in vivo by inhibition of TPMT,
Fig. 6 Single cell gel electrophoresis (Comet assay) of HepaRG
cells incubated with a medium serving as control, b allopurinol
(100 μM), c AZA (70 μM) and d AZA 70 (μM) and allopurinol
(100 μM). HepaRG cells were embedded in low melting agarose
on a slide, then lysed and treated with alkaline for DNA
unwending followed by alkaline electrophoresis (pH>13).
Following SYBR Green I staining, nuclei were visualised under
an epifluorescence microscope. Damaged DNA migrates towards
the anode, resulting in a comet tail. AZA azathioprine
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leading to a decline in 6-MMP levels (Szumlanski and
Weinshilboum 1995; Dubinsky et al. 2000; de Graaf
et al. 2010). However, there is much debate about the
clinical significance of this interaction (Actis et al.
2009). The interaction between 5-ASA and thiopurines
is non-competitive, and long-term 5-ASA therapy did
not affect TPMT enzyme activity in a prospective study
in CD patients (Szumlanski and Weinshilboum 1995;
Dilger et al. 2007). Unfortunately, measurement of 5-
ASA influences on TPMT activity is technically not
feasible to our knowledge, because 5-ASA is removed
in the washing steps (Dilger et al. 2007). In our in vitro
study, the effects of 5-ASA on cytotoxicity were limited
compared to allopurinol. This is supported by the find-
ing that 5-ASA co-administration did not increase cas-
pase-3/7 activation.
In this study, we showed that concentration-based
TG is more cytotoxic than AZA or 6-MP, with IC50
values of 18 μM in HepaRG cells after 72-h incubation.
This probably results from a direct conversion of 6-TG
to 6-TGN, resulting in higher 6-TGN levels and less
other metabolites. The increased cytotoxicity of TGwith
allopurinol co-administered can be explained by XO
involvement in TG metabolism (Fig. 1). Our results of
single-drug assessments of AZA and 6-MP in HepaRG
cells are in accordance with those of Petit et al., who
compared HepaRG cells with human hepatocytes (Petit
et al. 2008). Furthermore, we showed a different toxicity
profile of AZA and 6-MP in Huh7 and HepG2 cells.
This might be explained by depletion of glutathione,
caused by the conversion of AZA to 6-MP, as previously
shown by Lee and Farrell (Lee and Farrell 2001). On the
other hand, in HepaRG cells, this difference was not that
prominent.
We measured both TPMT activity as well as the
most prevalent polymorphisms in the TPMT gene
(TPMT*2 and TPMT*3A, *3B), because TPMT ac-
tivity still varies in patients without these polymor-
phisms (Lennard 2013). Low TPMT activity is as-
sociated with high 6-TGN levels, which may cause
leucopenia (Shaye et al. 2007; Lennard 2013). The
three hepatoma cell lines tested had identical TPMT
genotypes, but a variance in TPMT activity was
noticed. Hence, no direct relation with cytotoxicity
was found. It is difficult to compare TPMT activity
we measured with those in clinical studies as herein
TPMT activity is measured in erythrocytes (Ford
and Berg 2003).
Unfortunately, our HPLC method could not discrim-
inate 6-TGN from AZA or 6-MP. This would be of
particular interest, as that would allow the production
of a dose response curve comparing the association
between 6-TGN levels and cytotoxicity. Despite the fact
that the used HPLC protocol was not intended and
validated for cell line research, our study is still unique,
providing direct evidence of the in vitro metabolism of
AZA in the HepaRG cell line demonstrated by the
formation of 6-MMP. Another limitation of this study
is the lack of comparison with human hepatocytes. It has
to be stressed that incubation experiments with human
hepatocytes also have their limitations, as human hepa-
tocytes are difficult to obtain and their metabolic activ-
ities rapidly decline during culturing (Gomez-Lechon
et al. 2003; Guillouzo et al. 2007; Szabo et al. 2013).
HepaRG cells are currently considered as the best sur-
rogate for human hepatocytes for use in drug toxicity
studies and are closer related to human hepatocytes than
rat hepatocytes because of the high conservation of
metabolic enzymes and the absence of interspecies dif-
ferences (Parent et al. 2004; Guillouzo et al. 2007; Hart
et al. 2010; Andersson et al. 2012; Szabo et al. 2013).
With the notion that HepG2 and Huh7 cells have been
used more extensively in in vitro experiments so far, we
Fig. 7 Caspase-3/7 activation of HepaRG cells incubated 24 h
with medium (control), 5-ASA (200 μM), allopurinol (100 μM),
AZA (70 μM) or a combination of both. Staurosporine (2 μM)
was used as positive control. Activation of cells incubated only
with medium was set as control. Values are presented as mean of
two experiments with the SEM. Differences were compared with
the Mann–Whitney U test. AZA azathioprine, 5-ASA 5-
aminosalicylic acid, SEM standard error of the mean
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also used these cell lines for comparison (Guo et al.
2011). In accordance with previous studies (Petit
et al. 2008; Hart et al. 2010; Andersson et al.
2012), we showed that HepaRG cells express the
highest levels of important drug metabolising en-
zymes. In order to create similar experimental con-
ditions for the three cell lines, we used the same
culture medium for all three cell lines, which in-
cludes addition of 2 % DMSO according to the
HepaRG culturing protocol (Gripon et al. 2002).
DMSO is used to induce or maintain cell differenti-
ation in HepaRG cells (Gripon et al. 2002; Narimatsu
et al. 2006; Sainz and Chisari 2006; Choi et al.
2009). Because previous studies with HepG2 and
Huh7 cells did not use DMSO, this can be considered
as a limitation. However, our results demonstrate that
the upregulation of drug metabolising enzymes by
DMSO is not limited to HepaRG cells, results which
are in accordance with those of Choi et al. (Choi
et al. 2009).
In conclusion, in this in vitro study, we could dem-
onstrate a considerable increase of thiopurine-induced
cytotoxicity by co-treatment with a non-toxic dose of
allopurinol.
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